Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by IvyRock Asset Management HK Ltd

IvyRock Asset Management HK Ltd trimmed its holdings in shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) by 3.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 770,200 shares of the company’s stock after selling 30,800 shares during the quarter. Legend Biotech accounts for about 8.1% of IvyRock Asset Management HK Ltd’s holdings, making the stock its 4th largest position. IvyRock Asset Management HK Ltd’s holdings in Legend Biotech were worth $15,319,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. boosted its position in Legend Biotech by 2.1% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 177,268 shares of the company’s stock worth $3,526,000 after purchasing an additional 3,707 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Legend Biotech in the 3rd quarter valued at $136,000. China Universal Asset Management Co. Ltd. grew its stake in Legend Biotech by 25.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,805 shares of the company’s stock valued at $316,000 after purchasing an additional 3,372 shares during the period. Asset Management One Co. Ltd. increased its position in shares of Legend Biotech by 20.9% during the 3rd quarter. Asset Management One Co. Ltd. now owns 12,782 shares of the company’s stock valued at $254,000 after purchasing an additional 2,207 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in shares of Legend Biotech by 11.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 23,892 shares of the company’s stock valued at $475,000 after purchasing an additional 2,406 shares during the last quarter. 70.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Legend Biotech

In other news, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the company’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $9.46, for a total transaction of $258,920.20. Following the transaction, the director owned 52,731 shares of the company’s stock, valued at $498,835.26. This represents a 34.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Carlos E. Santos sold 5,430 shares of the stock in a transaction on Monday, September 21st. The stock was sold at an average price of $9.14, for a total value of $49,630.20. Following the transaction, the chief financial officer owned 14,246 shares of the company’s stock, valued at $130,208.44. The trade was a 27.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.02% of the company’s stock.

Trending Headlines about Legend Biotech

Investors following LEGN have been watching these headlines:

• Positive Sentiment: Recent coverage highlights growth in CARVYKTI sales, a potential support for Legend Biotech’s commercial outlook. Is Legend Biotech (LEGN) Reasonable After CARVYKTI Sales Growth?
• Neutral Sentiment: Third-quarter results were mixed: revenue increased 32% year over year to $359.5 million, slightly below estimates, while EPS of $0.14 beat the $0.01 consensus. The earnings-call transcript provides further context on the quarter. Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript
• Negative Sentiment: Four firms lowered their price targets, signaling more cautious expectations: Morgan Stanley cut its target to $43 but kept Overweight; Oppenheimer lowered to $25 and retained Market Perform; RBC cut to $50 while maintaining Outperform; and Barclays reduced its target to $61 but stayed Overweight. Analysts Offer Insights on Healthcare Companies: Align Tech and Legend Biotech

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on LEGN shares. Weiss Ratings upgraded Legend Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. HC Wainwright restated a “buy” rating on shares of Legend Biotech in a research report on Friday, October 30th. JPMorgan Chase & Co. reduced their price target on shares of Legend Biotech from $35.00 to $33.00 and set a “neutral” rating for the company in a research report on Friday, October 9th. UBS Group restated a “buy” rating and set a $65.00 price objective on shares of Legend Biotech in a report on Monday, September 28th. Finally, Oppenheimer lowered their price objective on shares of Legend Biotech from $40.00 to $25.00 and set a “market perform” rating on the stock in a research report on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.85.

Legend Biotech Stock Down 5.1%

NASDAQ:LEGN opened at $18.54 on Friday. Legend Biotech Corporation Sponsored ADR has a 12 month low of $16.24 and a 12 month high of $37.50. The firm’s 50 day moving average is $19.66 and its 200 day moving average is $22.12.

Legend Biotech (NASDAQ:LEGN) last announced its quarterly earnings data on Tuesday, November 10th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The business had revenue of $359.50 million during the quarter, compared to analyst estimates of $361.46 million. During the same period in the prior year, the company earned ($0.05) earnings per share. Legend Biotech’s revenue was up 32.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Legend Biotech Corporation Sponsored ADR will post -0.08 earnings per share for the current year.

Legend Biotech Profile

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.